Valuation: Caplin Point Laboratories Limited

Market Cap 173B 1.81B 1.62B 1.5B 1.36B 2.54B 2.59B 18.06B 7.14B 90.29B 6.81B 6.66B 286B P/E 2027 *
23.8x
P/E 2028 * 20.5x
Enterprise Value 173B 1.81B 1.62B 1.5B 1.36B 2.54B 2.59B 18.06B 7.14B 90.29B 6.81B 6.66B 286B EV / Sales 2027 *
6.89x
EV / Sales 2028 * 6.09x
Free-Float
26.56%
Yield 2027 *
0.18%
Yield 2028 * 0.18%
1 day+2.22%
1 week-1.25%
Current month-16.14%
1 month-19.90%
3 months-7.84%
6 months+32.31%
Current year+23.37%
1 week 2,177
Extreme 2177
2,306.2
1 month 2,177
Extreme 2177
2,871.8
Current year 1,502.45
Extreme 1502.45
2,990.6
1 year 1,502.45
Extreme 1502.45
2,990.6
3 years 977.1
Extreme 977.1
2,990.6
5 years 575
Extreme 575
2,990.6
10 years 180
Extreme 180
2,990.6
Manager TitleAgeSince
Chief Executive Officer 71 2015-03-27
Director of Finance/CFO - 2016-02-18
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 73 2010-01-26
Director/Board Member - 2025-11-04
Director/Board Member 71 2015-03-27
Change 5-day change 1-year change 3-year change Capi.($)
+2.22%-1.25%+13.50%+128.75% 1.78B
+0.45%+1.76%+54.96%+118.11% 1,135B
+0.94%+4.20%+39.86%+75.69% 635B
+0.39%+0.46%+25.77%+97.40% 505B
+1.43%+4.56%+46.20%+66.91% 378B
-3.21%-3.66%+60.72%+35.68% 358B
-0.41%+2.23%+22.48%+48.54% 295B
+0.23%+3.28%+2.57%+21.89% 266B
+1.22%+2.81%+52.40%+63.37% 237B
+1.70%+1.60%+31.21%+102.44% 193B
Average +0.38%+1.10%+34.97%+75.88% 400.54B
Weighted average by Cap. +0.14%+1.63%+41.39%+81.05%

Financials

2027 *2028 *
Net sales 25.07B 263M 236M 218M 197M 369M 376M 2.62B 1.04B 13.11B 989M 968M 41.5B 28.34B 298M 266M 246M 223M 417M 425M 2.96B 1.17B 14.82B 1.12B 1.09B 46.91B
Net income 7.26B 76.33M 68.29M 63.16M 57.22M 107M 109M 760M 301M 3.8B 286M 280M 12.02B 8.41B 88.37M 79.07M 73.13M 66.25M 124M 126M 880M 348M 4.4B 332M 325M 13.92B
Net Debt - -
Projected Income Statement - Annual - Caplin Point Laboratories Limited
Logo Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
4,199
Date Price Change Volume
26-10-26 ₹2,271.50 +2.22% 9,026
26-10-23 ₹2,222.15 -1.26% 10,845
26-10-22 ₹2,250.40 +1.31% 4,226
26-10-21 ₹2,221.20 -1.81% 12,405
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Caplin Point Laboratories Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2,271.50INR
Average target price
2,765.00INR
Spread / Average Target
+21.73%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Caplin Point Laboratories Limited
  1. Stock Market
  2. Stocks
  3. CAPLIPOINT Stock